🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
230.26
-6.19 (-2.62%)
At close: Nov 20, 2026, 4:00 PM EST
230.62
+0.36 (0.16%)
After-hours: Nov 20, 2026, 7:30 PM EST

Jazz Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 22 analysts polled by S&P Global, Jazz Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $297.5. The average 1-year stock price forecast is 29.20% higher than the current stock price, while the lowest is $220 (-4.46%) and the highest is $330 (+43.32%).

Price Target: $297.5 (+29.20%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$220$297.5$300$330
Change-4.46%+29.20%+30.29%+43.32%

Analyst Ratings

The average analyst rating for Jazz Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy101111131313
Buy777777
Hold112222
Sell110000
Strong Sell000000
Total192020222222

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Needham
Needham
Buy
Maintains
$310 → $308
BuyMaintains$310 → $308+33.76%Nov 16, 2026
Morgan Stanley
Morgan Stanley
Buy
Maintains
$319 → $324
BuyMaintains$319 → $324+40.71%Nov 13, 2026
UBS
UBS
Buy
Maintains
$326
BuyMaintains$326+41.58%Nov 13, 2026
Piper Sandler
Piper Sandler
Buy
Reiterates
$310 → $330
BuyReiterates$310 → $330+43.32%Nov 12, 2026
Bank of America Securities
Bank of America Securities
Buy
Reiterates
$313
BuyReiterates$313+35.93%Nov 3, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
4.81B
from 4.27B
Increased by 12.68%
Revenue Next Year
5.07B
from 4.81B
Increased by 5.34%
EPS This Year
14.90
from 8.38
Increased by 77.86%
EPS Next Year
26.74
from 14.90
Increased by 79.43%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026E
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
3.09B3.66B3.83B4.07B4.27B4.81B
Revenue Growth
30.91%18.26%4.78%6.12%4.88%12.68%
Gross Profit
2.88B3.39B3.55B3.76B3.91B4.35B
Gross Margin
92.97%92.70%92.59%92.36%91.67%90.46%
Operating Income
475.26M839.14M816.23M864.14M1.02B1.38B
Net Income
-329.67M-224.06M414.83M560.12M-356.15M267.04M
EPS
----8.3814.90
EPS Growth
-----59.90%77.86%
Forward PE
8.238.546.295.727.6715.45
Free Cash Flow
----1.30B1.15B
No. Analysts
-----21
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High4.9B
Avg4.8B
Low4.8B

Revenue Growth

Revenue Growth202620272028
High
13.6%
Avg
12.7%
Low
11.8%

EPS Forecast

EPS202620272028
High15.97
Avg14.90
Low13.98

EPS Growth

EPS Growth202620272028
High
90.6%
Avg
77.9%
Low
66.8%